Last reviewed · How we verify

Vifor Fresenius Medical Care Renal Pharma — Portfolio Competitive Intelligence Brief

Vifor Fresenius Medical Care Renal Pharma pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Difelikefalin Injection Difelikefalin Injection phase 3 Kinin B1 receptor agonist Kinin B1 receptor (B1R) Nephrology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Vifor Fresenius Medical Care Renal Pharma:

Cite this brief

Drug Landscape (2026). Vifor Fresenius Medical Care Renal Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vifor-fresenius-medical-care-renal-pharma. Accessed 2026-05-18.

Related